Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate ... ECGs, clinical laboratory tests, physical examinations, and visual analogue mood ...

Effects on clinical parameters including days with lesions ... into Phase 1b studies after each long-acting helicase-primase inhibitor candidate exceeded the company’s target PK profiles in Phase 1a ...

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to ...

Moderna Inc (NASDAQ:MRNA) saw its stock rise 3.8% after announcing that its experimental flu vaccine, mRNA-1010, delivered ...

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging ...

Liver and Lipid Profile ... is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders.

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative ...

Phase 3 Top Line Results Expected Q2 2026 SALT LAKE CITY, June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biophar ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical ...